Telix Pharma is a surprise inclusion in December. The add, float and capping changes lead to an estimated one-way turnover of 5.5% and to a round-trip trade of A$290m.
What is covered in the Full Insight:
Introduction to MV Australia Equal Weight Index
December Rebalance Details
Impact of Telix Pharmaceuticals Addition
Analysis of Passive Flows and Short Interest
Concluding Thoughts
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.